{
    "clinical_study": {
        "@rank": "19830", 
        "acronym": "CSAPPPCC", 
        "arm_group": {
            "arm_group_label": "albumin-bound paclitaxel plus nedaplatin", 
            "arm_group_type": "Experimental", 
            "description": "albumin-bound paclitaxel plus nedaplatin: Intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed."
        }, 
        "brief_summary": {
            "textblock": "Using albumin-bound paclitaxel and nedaplatin in the advanced or recurrent metastasis\n      cervical cancer, to evaluate the efficacy and toxic reaction."
        }, 
        "brief_title": "Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Uterine Cervical Cancer", 
        "condition_browse": {
            "mesh_term": "Uterine Cervical Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Albumin-bound paclitaxel is a novel, solvent-free, albumin-bound nanoparticle form of\n      paclitaxel designed to avoid problems associated with solvents used in Taxol.  And\n      albumin-bound paclitaxel was characterized with high tolerated doses with greater efficacy,\n      and with greater concentration in tumor tissue compared with normal tissues.  This is a\n      single center, non-randomized, open-label Phase II clinical study to investigate the\n      efficacy and tolerability of albumin-bound paclitaxel plus nedaplatin in patients with\n      advanced, recurrent metastatic cervical cancer.  About 30 patients will receive 175-200\n      mg/m2 albumin-bound paclitaxel, d 1 combined with 80- 100 mg/m2  nedaplatin, d 2, every 3\n      weeks. At least 2 cycles will be completed for each patient, for whom responded to the\n      treatment, 4-6 cycles will be completed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Cervical cancer, advanced or recurrent metastasis\n\n          -  Measurable and assessible tumor lesions\n\n          -  Used ordinary paclitaxel or platinum drugs, more than 28 days\n\n          -  Aged 18-70\n\n          -  KPS score> 60 points, expected to survive more than 3 months\n\n          -  Normal bone marrow function\n\n          -  The function of liver and kidney had no obvious damage\n\n          -  Normal function of vital organs\n\n          -  No brain metastases\n\n          -  Patients or their agents to sign informed consent\n\n          -  Compliance, and can be followed up regularly\n\n        Exclusion Criteria:\n\n          -  Brain metastases\n\n          -  Serious complications\n\n          -  Acute inflammatory response\n\n          -  Combined with other tumor\n\n          -  Pregnancy or breast-feeding women\n\n          -  Vertebral metastasis with nerve compression symptoms\n\n          -  Large volume of pleural effusion, pericardial effusion\n\n          -  Other malignancy within five years\n\n          -  Drug allergy\n\n          -  Other chemotherapy contraindications\n\n          -  The possibility of pregnancy, and not willing to contraception\n\n          -  No measurement of lesion\n\n          -  Mental illness which is difficult to control"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01667211", 
            "org_study_id": "CH-GYN-001", 
            "secondary_id": "11-92/527"
        }, 
        "intervention": {
            "arm_group_label": "albumin-bound paclitaxel plus nedaplatin", 
            "description": "intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.", 
            "intervention_name": "albumin-bound paclitaxel plus nedaplatin", 
            "intervention_type": "Drug", 
            "other_name": "Abraxane (albumin-bound paclitaxel)"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Nedaplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Advanced uterine cervical cancer", 
        "lastchanged_date": "August 21, 2012", 
        "location": {
            "contact": {
                "email": "super0078888@sina.com", 
                "last_name": "Rong Zhang", 
                "phone": "008613911982343"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100021"
                }, 
                "name": "Chinese Academy of Medical Sciences, Cancer Hospital, Gynecologic Oncology"
            }, 
            "investigator": {
                "last_name": "Rong Zhang", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single Center, Non-randomized, Open Phase II Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Patients With Advanced, Recurrent Metastatic Cervical Cancer", 
        "overall_contact": {
            "email": "super0078888@sina.com", 
            "last_name": "Rong Zhang", 
            "phone": "008613911982343"
        }, 
        "overall_official": {
            "affiliation": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences", 
            "last_name": "Rong Zhang", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Percentage of patients who achieve partial response (PR)/ complete response (CR) based on RECIST", 
            "measure": "response rate", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01667211"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese Academy of Medical Sciences", 
            "investigator_full_name": "Zhang rong", 
            "investigator_title": "Chief Physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Measure of time from study treatment to disease progression", 
                "measure": "Time to progression (TTP)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Percentage of patients who have PFS two years after receiving study treatment.", 
                "measure": "2-year progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Percentage of patients who experience an adverse event during this study.", 
                "measure": "safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Measure of time from study treatment to patient's death or lost to follow-up.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Chinese Academy of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese Academy of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}